title: Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
abstract: The prognosis of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) remains poor and current treatments are typically of limited benefit. Histone deacetylase (HDAC) inhibitors have proven effective for the treatment of relapsed/refractory PTCL. To date approved HDAC inhibitors for patients with T-cell lymphoma are vorinostat, romidepsin and, recently, belinostat. Here we review the pharmacology and the clinical activity of belinostat. Belinostat is a well-tolerated HDAC inhibitor that has shown activity in heavily pretreated patients with relapsed/refractory PTCL. Several clinical trials are currently investigating the use of belinostat in different cancers and in combination with other chemotherapeutic agents.
authors.affiliation: 1Division of Oncology, Washington University School of Medicine, 660 S Euclid Avenue, Campus Box 8007, St Louis, MO 63110, USA.
authors.forename: Armin
authors.initials: A
authors.lastname: Rashidi
authors.affiliation: 1Division of Oncology, Washington University School of Medicine, 660 S Euclid Avenue, Campus Box 8007, St Louis, MO 63110, USA.
authors.forename: Amanda F
authors.initials: AF
authors.lastname: Cashen
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D006877:Hydroxamic Acids / Q000737:chemistry / Q000627:therapeutic use*; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D012008:Recurrence; D019233:Retreatment; D013449:Sulfonamides / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D013449:Sulfonamides; C487081:belinostat
keywords: T-cell lymphoma; belinostat; histone deacetylase inhibitor